Betnocin-N® Cream
Topical Anti-inflammatory & Antibiotic

¤ Betnocin-N® contains two active components:

  • Betamethasone valerate, a glucocorticoid that has potent anti-inflammatory action.
  • Neomycin sulphate, an aminoglycoside that is bactericidal antibacterial, active against most Gram-negative and some Gram-positive organisms.

¤ Betnocin-N® ointment  is preferred for dry lesions and particularly useful for skin areas where topical absorption is poor such as the palm, sole, elbow and knees, while Betnocin-N® cream  is useful for moist or weeping skin like face, neck, axilla.

¤ Betnocin-N® ointment / cream possess antipruritic, and anti-inflammatory actions.

Each tube Betnocin-N® ointment / cream  contains:

  • Betamethasone  0.1% w/w  (as Betamethasone valerate)    
  • Neomycin sulphate BP  0.5% w/w 

Betnocin-N® is indicated for

  • infections of the skin or mucous membranes.
  • Inflammatory dermatoses such as eczema, seborrhoeic or atopic dermatitis, neurodermatitis, psoriasis, inflammatory phase of xerosis, contact dermatitis, insect bites.
  • Hypersensitivity to any components of the formulation;
  • Skin viral infections, rosacea, acne, peri-oral dermatitis, peri-anal and genital pruritus, ulcerative conditions, untreated fungal infection, primary cutaneous viral infections (e.g. herpes simplex, chickenpox);
  • Dermatoses in children under 1 year of age, including dermatitis and napkin eruptions.

In case of prolonged use or application on extensive area, the following interactions must be considered:

  • Concurrent use of corticosteroids with potassium-depleting diuretics may enhance hypokalemia; patient should have serum potassium level determinations at frequent intervals.
  • Concurrent use of corticosteroids with cardiac glycosides (digoxin) may enhance the possibility of arrhythmia of digitalis toxicity.  
  • The ulcerogenic potential of NSAIDs may be increased when used concurrently with corticosteroids.
  • Concurrent use of corticosteroids with hypoglycemics may increase blood glucose levels; dosage adjustment of the antidiabetic agent is needed.  
  • Corticosteroids may reduce serum salicylate levels by increasing metabolism and/or clearance. Concurrent use needs caution especially in hypoprothrombinemia.
  • Although reports are conflicting, caution is recommended when corticosteroids are used together with anticoagulants especially in patients prone to gastrointestinal ulceration and hemorrhage. 

Common side effects are

  • epidermal and dermal atrophy resulting in the thinning of the skin;

less common local effects are

  • rosacea-like dermatosis, perioral dermatitis, folliculitis and non healing of leg ulcers and telangiectasis and purpura, and acne form pustules at the site of application.
  • Hypo-pigmentation occurs especially in black skin, infants and elderly patients. 
  • Patients aged 12 years or less: use is not recommended.
  • Patients over 12 years: apply a thin film 2 – 3 times daily.
  • Don’t apply to wet skin unless directed.
  • Don’t apply to face or inguinal area.
  • Don’t cover with occlusive dressing.
  • Not for alternate day therapy.
  • Caution in secondary infection, children.
  • Avoid long-term continuous therapy especially on face, large areas or broken skin. If used on the face, courses should be limited, if possible, to five days, and occlusion should not be used.   
  • Avoid contact with eyes. 
  • Prolonged use and/or application on extensive area should be avoided during pregnancy and lactation.
  • Betnocin-N® is usually well tolerated but if signs of hypersensitivity appear, application should be stopped immediately.
  • Betnocin-N® cream : tube of 15gm.
  • Betnocin-N® ointment : tube of 15gm.
  • Betnocin-N® cream: Store below 25ºC.
  • Betnocin-N® ointment: Store below 25ºC.